MarketPulse

VYVGART

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Muscular Dystrophy Association

FDA Expands VYVGART Approval to All Generalized Myasthenia Gravis Patients

FDA expands VYVGART approval to include seronegative myasthenia gravis patients, broadening treatment access and increasing commercial opportunity for Ultragenyx.
ARGXFDA approvalclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx

argenx to Report Q1 2026 Results; Immunology Firm Signals Strategic Update

argenx will report Q1 2026 financial results on May 7, 2026, offering investors insight into the immunology company's clinical progress and commercial trajectory.
ARGXautoimmune diseasesconference call
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx Se

argenx Expands VYVGART Leadership with Positive Phase 3 Data Across MG and CIDP

argenx presents Phase 3 data supporting VYVGART expansion across ocular MG, seronegative MG, and treatment-naïve CIDP, with 87.5% early benefit rates.
ARGXFDA approvalPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Argenx's Vyvgart Poised for Explosive Growth as Autoimmune Market Expands

Argenx's Vyvgart gains momentum with Japan approval and Fujifilm partnership, positioning the FcRn inhibitor for significant market expansion across multiple autoimmune indications through 2030.
ARGXFUJIYVYVGARTbiologic therapy
BenzingaBenzinga··Vandana Singh

Argenx Reports Phase 3 Success for VYVGART in Ocular Myasthenia Gravis

Argenx's VYVGART achieves Phase 3 success for ocular myasthenia gravis, meeting primary endpoint. Company plans FDA application to expand indication for the rare eye disorder treatment.
ARGXPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx Se

argenx's VYVGART Meets Primary Endpoint in Ocular Myasthenia Gravis Trial

argenx's VYVGART met its primary endpoint in a Phase 3 ocular myasthenia gravis trial, showing significant symptom improvements. The company plans FDA approval for label expansion.
ARGXFDA approvalPhase 3 trial